Verve Therapeutics VERV 深 沪
交易中 03-31 09:58:16 美东时间
11.13
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 11.13
- 总市值 9.94亿
- 52周最高 11.405
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.8647
- 委 比 0.00%
- 总股本 8931.22万
- 历史最高 78.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.8647
- 每 手 1
- 风险率 3.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CAMP4 Appoints Michael MacLean to its Board of Directors
CAMP4 Therapeutics announced the appointment of Michael MacLean to its Board of Directors. With over 35 years of financial and operational leadership in biotechnology, MacLean brings extensive experience in growing innovative biotech companies. His expertise will support CAMP4 as it advances its CMP-002 program toward a Phase 1/2 clinical trial for SYNGAP1-related disorder, for which there are currently no approved treatments. MacLean previously ...
03-24 11:00
超30亿美元！这家MNC持续押注尚无药物的听力损伤赛道
（来源：动脉新医药） 1月28日，Seamless Therapeutics与礼来签订全球战略研究合作和许可协议。根据协议条款，Seamless将利用其专有重组...
01-29 18:34
Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly LLY.N signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and c
01-28 20:00
UPDATE 2-Merck's cholesterol drug gets a boost with another late-stage trial success
Adds background on the drug and other treatments in paragraphs 7 to 10 Sept 2 (Reuters) - Merck's MRK.N oral drug met the main goal of reducing bad cholesterol in a late-stage trial, it said on Tuesda...
2025-09-02 19:04
Eli Lilly Reports Q2 2025 Revenue Surge of 38% to $15.56 Billion, EPS Up 92% to $6.29
Eli Lilly and Company announced its second-quarter 2025 financial results, reporting a 38% increase in revenue to $15.56 billion. This growth was primarily driven by volume increases in key products Z...
2025-08-07 18:46
Verve Therapeutics Announces Merger and Nasdaq Delisting
Verve Therapeutics ( ($VERV) ) just unveiled an update. Verve Therapeutics has ...
2025-07-26 04:51
Eli Lilly And Verve Therapeutics Announces That The Tender Offer For All Outstanding Verve Shares, Priced At $10.50 Per Share In Cash Plus A Potential Additional $3.00 Via A Non-Tradable Contingent Value Right, Officially Expired At 12:01 A.M. Et On July 24, 2025. The Offer Was Not Extended.
Eli Lilly and Company (NYSE:LLY) and Verve Therapeutics, Inc. (NASDAQ:VERV) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common stock in exchange for
2025-07-24 20:05
Lilly and Verve announce expiration of Verve tender offer
INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued ...
2025-07-24 20:00
Verve Therapeutics Announces Retention Bonus Program for Executives
Verve Therapeutics ( ($VERV) ) has shared an announcement. Verve Therapeutics a...
2025-07-15 18:45
